公开(公告)号：US20210107879A1

公开(公告)日：2021-04-15

申请号：US17122442

申请日：2020-12-15

Applicant: Wisconsin Alumni Research Foundation

Inventor： Timothy Bugni ,  Fan Zhang ,  Douglas Braun ,  Gene Ananiev ,  F. Michael Hoffmann

IPC: C07D239/22

Abstract: The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.

公开(公告)号：US11618734B2

公开(公告)日：2023-04-04

申请号：US17122442

申请日：2020-12-15

Applicant: Wisconsin Alumni Research Foundation

Inventor： Timothy Bugni ,  Fan Zhang ,  Douglas Braun ,  Gene Ananiev ,  F. Michael Hoffmann

IPC: C07D239/22

Abstract: The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.

公开(公告)号：US10889551B2

公开(公告)日：2021-01-12

申请号：US16551534

申请日：2019-08-26

Applicant: Wisconsin Alumni Research Foundation

Inventor： Timothy Bugni ,  Fan Zhang ,  Douglas Braun ,  Gene Ananiev ,  F. Michael Hoffmann

IPC: C07D239/22

Abstract: The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.

公开(公告)号：US20150011492A1

公开(公告)日：2015-01-08

申请号：US14322630

申请日：2014-07-02

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： F. Michael Hoffmann ,  K. Craig Kent ,  Shakti Goel ,  Lian-Wang Guo ,  Toshio Takayama

IPC: A61K31/704 ,  A61F2/82 ,  A61K31/517 ,  A61K31/436 ,  A61K31/047

CPC classification number: A61K31/704 ,  A61F2/82 ,  A61F2250/0067 ,  A61K31/047 ,  A61K31/05 ,  A61K31/436 ,  A61K31/517 ,  A61K47/10 ,  A61K47/34 ,  A61K2300/00

Abstract: The present invention relates generally to the pathology of restenosis. In particular, provided herein are devices comprising a compound that selectively decreasing smooth muscle cell proliferation without a substantial decrease in endothelial cell proliferation. Also provided are methods of using such devices to treat, prevent, or reduce vascular disease or the likelihood of restenosis following angioplasty.

Abstract translation: 本发明一般涉及再狭窄的病理学。 特别地，本文提供了包含选择性地降低平滑肌细胞增殖而不显着降低内皮细胞增殖的化合物的装置。 还提供了使用这种装置治疗，预防或减少血管疾病或血管成形术后再狭窄的可能性的方法。

公开(公告)号：US20200062715A1

公开(公告)日：2020-02-27

申请号：US16551534

申请日：2019-08-26

Applicant: Wisconsin Alumni Research Foundation

Inventor： Timothy Bugni ,  Fan Zhang ,  Douglas Braun ,  Gene Ananiev ,  F. Michael Hoffmann

IPC: C07D239/22

Abstract: The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.